Bladder Cancer VL

Defining BCG-Unresponsive and The Pathway to Clinical Trials in Treating NMIBC - Ashish Kamat

Details
Ashish Kamat, MD discusses the focus of the International Bladder Cancer Group, discussing the pathway to developing the definition of BCG-unresponsive. Today the unified definition of BCG-unresponsive disease essentially denotes those patients for whom any more BCG is futile. This has opened the door to many ongoing clinical trials. The discussion moves to review these trials, including Nadofarag...

BCG Shortage 2019: Managing Through Treatment and Reimbursement Issues - Neal Shore, Ashish Kamat, and Jonathan Rubenstein

Details
Neal Shore discusses the current 2019 shortage of BCG with Ashish Kamat and Jonathan Rubenstein. Bacillus Calmette-Guérin (BCG) is used as first-line intravesical therapy following tumor resection of non–muscle-invasive bladder cancer. Bacille Calmette-Guérin (BCG) has been a standard of care for many patients with non-muscle invasive bladder cancer for decades.Merck & Co., Inc., has advised that...

2019 BCG Shortage-Perspectives from Josh Meeks

Details
Josh Meeks and Alicia Morgans discuss the clinical treatment of high-risk NMIBC in a BCG rationed era. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern...

Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...

The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten

Details
Sima Porten speaks about the importance of TURBT and the benefits of enhanced cystoscopy to the patient. She references the new AUA/SUO guidelines recommendation for enhanced cystoscopy and the benefit of Blue Light with Cysview®. Biography: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Related Content: Efficacy and Safety of Blue Light Flexible Cystoscop...

Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand

Details
Siamak Daneshmand reviews the objectives of the Blue Light Cystoscopy with Cysview® flexible study, "Efficacy and Safety of Flexible BLC with Cysview in the Surveillance of Bladder Cancer". The main objective points discussed are whether or not flexible BLC cystoscopy resulted in increase detection of non-muscle invasive bladder cancer, particularly CIS and to see if repeat use of Cysview was safe...

Patient Reported Outcomes in the Use of Blue Light Cystoscopy in the Surveillance of Bladder Cancer - Angela B. Smith

Details
Angela Smith reviews the patient reported outcomes (PROs) outlined in the article "Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer". Angela’s discussion includes how these PROs are incorporated into clinical practice and into the management of bladder cancer patients. Biography: Angela B. Smith, MD, MS, Assistant Professor, Department of Surgery/Urology UNC...

Evolution of Technology and Technique in Bladder Cancer - Ashish Kamat

Details
(Length of Discussion: 10 min) Ashish Kamat and Alicia Morgans discuss the highlights of his presentation at LUGPA 2018, on the evolution of technology and technique when treating bladder cancer. The initial resection of the bladder is paramount to the path of management for these patients, including the type of anesthesia, angles of scopes, white light and blue light detection, narrow-band imagin...

Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn

Details
In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in ea...

Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat

Details
Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBBS , President, International Bl...
email news signup